Infliximab and nephrotic syndrome

Nephrology Dialysis Transplantation

Volumn 20, Issue 12, 2005, Pages 2824-2826

  Chin, George ^a,c   Luxton, Grant ^a   Harvey, Jennet M ^b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

Drug induced; Infliximab; Nephrotic syndrome

Indexed keywords

CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TAR;

ABDOMINAL SWELLING; ADULT; ARTICLE; ASCITES; CASE REPORT; CHILL; COUGHING; DYSPNEA; ELECTROPHORESIS; FEMALE; FEVER; HEMATURIA; HUMAN; KIDNEY BIOPSY; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PERIPHERAL EDEMA; PLEURA EFFUSION; PREGNANCY; PRIORITY JOURNAL; PROTEINURIA; PSORIASIS; RIGOR; TACHYCARDIA;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; KIDNEY GLOMERULUS; MICROSCOPY, ELECTRON; NEPHROTIC SYNDROME; PSORIASIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27944461472     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi180     Document Type: Article

References (16)

1. Reimold AM. TNFalpha as therapeutic target: New drugs, more applications. Curr Drug Targets Inflamm Allergy 2002; 1: 377-392
2. Al-Salem IH. Striking and rapid improvement of plaque posriasis with infliximab. A report of two cases. Dermatology 2003; 207: 54-56
3. Salvarani C, Cantini F, Olivieri I et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Care Res 2003; 49: 541-545
4. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003; 49: S112-S117
5. Gottenbery JE, Nerle-Vincent F, Bentaberry F et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: A followup report of tolerability and efficacy. Arthritis Rheum 2003; 48: 2019-2024
6. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthrits Rheum 2002; 46: 2571-2573
7. Singh R, Cuchacovich R, Huang W, Espinoza LR. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. J Rheumatol 2002; 29: 636-637
8. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Infamm Bowel Dis 2003; 9: 176-178
9. Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003; 22: 56-61
10. McIlwain L, Carter JD, Bin-Sagheer S, Vasey FB, Nord J. Hypersentivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 2003; 36: 411-413
11. Reichert LJM, Koene RAP, Wetzels JFM. Prognostic factors in idiopathic membranous nephropathy [editorial review]. Am J Kidney Dis 1998; 31: 1-11
12. Johnson RJ, Feehally J. Comprehensive Clinical Nephrology, 2nd Edition. Mosby/Elsevier: 2003; Chapter 22
13. Nangaku M, Alpers CE, Pippin J et al. Renal microvascular injury induced by antibody to glomerular endothelial cells is mediated by C5b-9. Kidney Int 1997; 52: 1570-1578
14. Orlando RA, Kerjaschki D, Farquhar MG et al. Megalin (gp330) possesses an antigenic eptiope capable of inducing passive Heymann nephritis independent of the nephritogenic eptitope in receptor-associated protein. J Am Soc Nephrol 1995; 6: 61-67
15. Kluth DC, Rees AJ. New approaches to modify glomerular inflammation. J Nephrol 1999; 12: 66-75
16. Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis 2002; 39: 706-712